Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 28, 2017

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Optic Neuritis
Interventions
DRUG

Clemastine

12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.

DRUG

Placebo

Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.

Trial Locations (1)

94158

RECRUITING

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

Moorfields Eye Hospital NHS Foundation Trust

OTHER

lead

University of California, San Francisco

OTHER